ASCO 2022 | Biomarker-directed therapy in black and white men with mCRPC

Despite having higher prostate cancer incidence, black men have been underrepresented in large-scale molecular prostate cancer surveys. The PROMISE precision medicine database is an academic collaboration to compile clinical and genomic data from men with metastatic castration-resistant prostate cancer (mCRPC). In this interview, Clara Hwang, MD, Henry Ford Health System, Detroit, MI, discusses the results of an analysis evaluating the proportion of non-Hispanic black and non-Hispanic white men with actionable molecular data, as defined by the presence of mismatch repair deficiency, homologous recombination repair deficiency, and tumor mutational burden. Similar overall rates of actionable molecular alterations were found in both cohorts of men, however higher rates of mismatch repair deficiency and lower frequency of PTEN alterations were observed in non-Hispanic black men. Non-Hispanic black men were also less likely to be prescribed targeted therapies when compared to non-Hispanic white men. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.